Bristol Myers Squibb (BMY) Non-Current Assets (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Non-Current Assets data on file, last reported at $59.3 billion in Q1 2026.

• Quarterly Non-Current Assets fell 3.85% year-over-year to $59.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $242.6 billion (down 5.89% YoY) and the FY2025 annual result came in at $60.6 billion, down 3.46% from the prior year.
• Non-Current Assets slipped to $59.3 billion in Q1 2026 per BMY's latest filing, from $60.6 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $72.9 billion in Q1 2022 and bottomed at $59.3 billion in Q1 2026.
• The 5-year median for Non-Current Assets is $65.4 billion (2023), against an average of $65.6 billion.
• The widest annual swing landed in 2022, when Non-Current Assets retreated 14.55%; it then climbed 4.71% in 2024.
• Tracing BMY's Non-Current Assets over 5 years: stood at $69.5 billion in 2022, then slipped by 8.85% to $63.4 billion in 2023, then slipped by 0.89% to $62.8 billion in 2024, then slipped by 3.46% to $60.6 billion in 2025, then fell by 2.28% to $59.3 billion in 2026.
• Per Business Quant, the three latest BMY Non-Current Assets figures stand at $59.3 billion (Q1 2026), $60.6 billion (Q4 2025), and $61.3 billion (Q3 2025).

Peer Comparison